Johnson D E, Munson D P, Thompson T R
Pediatrics. 1981 Nov;68(5):633-7.
Prenatal administration of glucocorticoids has been shown to decrease in incidence and severity of respiratory distress syndrome in premature infants, but little is known regarding the immediate economic impact of this reduction in respiratory morbidity. This study retrospectively examined 342 infants born during 1978 and 1979 and hospitalized in the University of Minnesota Hospitals. Comparison of survival and the hospital charges for infants whose mothers had not received prenatal glucocorticoid therapy showed that administration of glucocorticoids has a significant effect in lowering mortality in infants with birth weights between 750 and 1,249 gm (27 to 29 weeks' gestation). Glucocorticoid therapy was also effective in decreasing morbidity as reflected by hospital charges of surviving infants with birth weights between 1,250 and 1,749 gm (30 to 32 weeks' gestation). In both steroid-treated and nontreated mothers, prolongation of gestation decreases hospital charges in a linear fashion. The noted decrease in hospital costs should not justify prenatal glucocorticoid administration but should stimulate examination of long-term effects of the drug on surviving infants.
产前给予糖皮质激素已被证明可降低早产儿呼吸窘迫综合征的发病率和严重程度,但对于这种呼吸疾病发病率降低所带来的直接经济影响却知之甚少。本研究回顾性调查了1978年至1979年间在明尼苏达大学医院住院的342名婴儿。对母亲未接受产前糖皮质激素治疗的婴儿的存活率和住院费用进行比较后发现,对于出生体重在750至1249克(妊娠27至29周)的婴儿,给予糖皮质激素对降低死亡率有显著效果。糖皮质激素治疗对于降低出生体重在1250至1749克(妊娠30至32周)的存活婴儿的住院费用所反映的发病率也有效。在接受类固醇治疗和未接受治疗的母亲中,孕周延长均以线性方式降低住院费用。所指出的住院费用降低不应成为产前给予糖皮质激素的理由,而应促使人们对该药物对存活婴儿的长期影响进行研究。